DIAGNOSTIC CAPABILITIES OF 68GA-FAPI PET/CT IN GASTRIC CANCER

A K Mels, Zhanar Zhakenova, G. MUKHIT, E. AMANTAYEV, Jandos Amankulov

2025

Closed access Metadata (CSL-JSON)
DOI 10.52532/2521-6414-2025-3-77-502
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Relevance: Gastric cancer remains a significant medical issue due to its high incidence and mortality rates. Hybrid imaging techniques, including positron emission tomography/computed tomography (PET/CT), play an important role in the diagnosis of malignant tumors, including gastric cancer. The development and clinical evaluation of radiopharmaceuticals used in oncology continues to advance. The study aimed to evaluate the diagnostic capabilities of PET/CT using fibroblast activation protein inhibitor labeled with gallium-68 ([68Ga]FAPI-PET/CT) in gastric cancer. Methods: This review includes data from 8 clinical studies (both prospective and retrospective) comparing the diagnostic performance of [68Ga]FAPI-PET/CT and fluorodeoxyglucose labeled with fluorine-18 ([18F]FDG) in patients with histologically confirmed gastric cancer. The number of patients in the studies ranged from 13 to 112, totaling 379 patients. The parameters analyzed included maximum standardized uptake value (SUVmax), tumor-to-background ratio (TBR), and the sensi-tivity in detecting primary gastric tumors, as well as lymph node and peritoneal metastases. Results: According to multiple clinical studies, [68Ga]FAPI demonstrated higher SUVmax and TBR values compared to [18F]FDG, especially in the visualization of diffuse, mucinous, and signetring cell histological subtypes of gastric cancer. This is associated with strong expression of FAP in the tumor stroma, enabling effective tracer accumulation in affected areas. Furthermore, [68Ga]FAPI-PET/ CT showed higher sensitivity in detecting primary gastric lesions (100% vs. 53%), lymph node metastases (79% vs. 54%), and peritoneal metastases (96% vs. 55%) compared to [18F]FDG-PET/CT. In 11-67% of patients, the use of [68Ga]FAPI-PET/CT led to a change in tumor staging and influenced the formulation of an individualized treatment plan. Conclusion: [68Ga]FAPI-PET/CT demonstrated greater diagnostic performance compared to [18F]FDG-PET/CT in staging gastric malignancies, particularly in histological subtypes with low glycolytic activity. The method offers superior sensitivity and visualization of peritoneal, visceral, and lymphatic metastases, playing a crucial role in determining treatment strategies